Fabhalta
Authorised
This medicine is authorised for use in the European Union
Iptacopan
MedicineHumanAuthorised
Overview
Fabhalta is a medicine used in adults with paroxysmal nocturnal haemoglobinuria (PNH) to treat haemolytic anaemia.
PNH is a disease in which the excessive breakdown of blood cells results in anaemia (low levels of haemoglobin, the protein in red blood cells that carries oxygen around the body), thrombosis (blood clots in blood vessels), pancytopenia (low levels of blood cells) and dark urine (due to large amounts of haemoglobin being released into the urine).
PNH is rare, and Fabhalta was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 4 June 2020.
Fabhalta contains the active substance iptacopan.
Fabhalta is available as capsules to be taken by mouth twice a day. If one or more doses are missed, the medicine should be taken as soon as possible. If multiple doses are missed, patients should be monitored for signs and symptoms of haemolysis.
The medicine can only be obtained with a prescription.
For more information about using Fabhalta, see the package leaflet or contact your doctor or pharmacist.
The complement system is a set of proteins that is part of the immune system (the body’s natural defences). In patients with PNH, the complement system is over-active and damages the patients’ own blood cells.
The active substance in Fabhalta, iptacopan, blocks a protein of the complement system called ‘factor B’. By blocking factor B, Fabhalta prevents the complement system from damaging cells, especially red blood cells, thereby helping to relieve the symptoms of the disease.
Fabhalta was shown to be effective at increasing haemoglobin levels and reducing the need for blood transfusions in one main study involving 97 patients with PNH.
Patients in the study had been previously treated with ravulizumab or eculizumab (other medicines for PNH) for at least 6 months and still had anaemia. Patients took either Fabhalta or continued their treatment with ravulizumab or eculizumab.
After 24 weeks of treatment, the percentage of patients who achieved an increase in haemoglobin levels of at least 2 g/dL without blood transfusions was around 82% for patients on Fabhalta , compared with 2% of patients continuing on ravulizumab or eculizumab. Around 69% of patients taking Fabhalta achieved haemoglobin levels of at least 12 g/dL without blood transfusions, compared with around 2% of the patients taking ravulizumab or eculizumab.
Data from an additional study supported the use of Fabhalta in patients with PNH who had not been previously treated.
For the full list of side effects and restrictions with Fabhalta, see the package leaflet.
The most common side effects with Fabhalta (which may affect more than 1 in 10 people) include upper respiratory tract (nose and throat) infection, headache and diarrhoea. In the clinical studies, the most common serious side effect was urinary tract infection.
Based on how Fabhalta works, it may increase the risk of infections. Fabhalta must not be used by patients who have an ongoing infection caused by so-called encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type B. It must also not be used by patients who are not currently vaccinated against N. meningitidis and S.pneumoniae unless the risk of delaying treatment outweighs the risk of developing an infection from these bacteria.
Fabhalta was shown to be effective at increasing haemoglobin levels and reducing the need for blood transfusions in patients with PNH. The most common side effects are considered inconvenient but are not expected to pose a risk to patients. The European Medicines Agency therefore decided that Fabhalta’s benefits are greater than its risks and that it can be authorised for use in the EU.
The company that markets Fabhalta will provide doctor and patients with educational material on the risk of infections caused by encapsulated bacteria and of serious haemolysis following treatment termination.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fabhalta have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Fabhalta are continuously monitored. Suspected side effects reported with Fabhalta are carefully evaluated and any necessary action taken to protect patients.
Fabhalta received a marketing authorisation valid throughout the EU on 17 May 2024.
Product information
17/05/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Fabhalta
- Active substance
- Iptacopan hydrochloride monohydrate
- International non-proprietary name (INN) or common name
- Iptacopan
- Therapeutic area (MeSH)
- Hemoglobinuria, Paroxysmal
- Anatomical therapeutic chemical (ATC) code
- L04A
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Fabhalta is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
News on Fabhalta
This page was last updated on